Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of...read more
Aimmune Therapeutics, which is developing an oral immunotherapy to desensitize peanut allergies, raised $160 million by offering 10 million shares at $16.00, the high end of the range of $14 to $16.
Aimmune Therapeutics plans to list on the Nasdaq under the...read more
Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price...read more
US IPO Weekly Recap: A bad week besides biotech
Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of...read more
Go nuts!: Aimmune Therapeutics prices upsized IPO at $16, the high end of the range
Aimmune Therapeutics, which is developing an oral immunotherapy to desensitize peanut allergies, raised $160 million by offering 10 million shares at $16.00, the high end of the range of $14 to $16. Aimmune Therapeutics plans to list on the Nasdaq under the...read more
Week ahead: 10 IPOs set to price during the week of August 3
August 2015 kicks off with ten IPOs on the calendar for this week - more IPOs than all of August 2014 - after a ...read more
Peanut allergy biotech Aimmune Therapeutics sets terms for $125 million IPO
Aimmune Therapeutics, which is developing an oral immunotherapy designed to lessen the effects of peanut allergies, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price...read more